RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
RAF Proto Oncogene Serine, Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Genetic Disorders which include indications Solid Tumor, Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Unspecified Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Blood Cancer, Cervical Cancer, Chondrosarcoma, Chordoma, Craniopharyngioma, Endometrial Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Kidney Cancer (Renal Cell Cancer), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Liposarcoma, Low-Grade Glioma, Malignant Glioma, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Non-Small Cell Lung Carcinoma, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Prostate Cancer, Rectal Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Triple-Negative Breast Cancer (TNBC).
The latest report, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Genetic Disorders which include indications Solid Tumor, Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Unspecified Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Anaplastic Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Blood Cancer, Cervical Cancer, Chondrosarcoma, Chordoma, Craniopharyngioma, Endometrial Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Glioma, Head And Neck Cancer Squamous Cell Carcinoma, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2%li%Breast Cancer), Kidney Cancer (Renal Cell Cancer), Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis), Liposarcoma, Low-Grade Glioma, Malignant Glioma, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Myelofibrosis, Non-Small Cell Lung Carcinoma, Oropharyngeal Cancer, Osteosarcoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Prostate Cancer, Rectal Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma, Transitional Cell Cancer (Urothelial Cell Cancer) and Triple-Negative Breast Cancer (TNBC).
The latest report, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
- The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Apollomics Inc
Bayer AG
Chengdu Fanxi Biopharma Co Ltd
Deciphera Pharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
Jazz Pharmaceuticals Plc
Metagone Biotech Inc
Novartis AG
Quanta Therapeutics Inc
Samjin Pharm Co Ltd
Sirnaomics Ltd
SyntheX Inc
Takeda Pharmaceutical Co Ltd
Verastem Inc
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
(MG-005 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(MG-010 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
History of Events
APL-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
avutometinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
belvarafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
DCBCI-0902 - Drug Profile
Product Description
Mechanism Of Action
DCC-3084 - Drug Profile
Product Description
Mechanism Of Action
FNX-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FYA-1001 - Drug Profile
Product Description
Mechanism Of Action
JZP-815 - Drug Profile
Product Description
Mechanism Of Action
History of Events
naporafenibum - Drug Profile
Product Description
Mechanism Of Action
History of Events
regorafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
SJP-1601 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SJP-601 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit FLT, FLT3, FLT4, FMS, c-KIT, LYN, RAF1, RET, PDGFRa and PDGFRb for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit Pan-RAF Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit RAF for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit RAF1 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
STP-902 - Drug Profile
Product Description
Mechanism Of Action
STX-200 - Drug Profile
Product Description
Mechanism Of Action
tovorafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Nov 11, 2022: Day One announces upcoming presentations at 2022 Society for Neuro-Oncology Annual Meeting
Oct 04, 2022: Verastem Oncology announces RAMP VS-6766 clinical trials and corporate updates
Sep 21, 2022: Global Coalition for Adaptive Research announces that Regorafenib has completed follow-up in the Gbm Agile trial for patients with glioblastoma
Jun 15, 2022: FDA grants IND clearance for Jazz and Redx’s cancer drug application
Jun 12, 2022: Day One announces positive initial data from pivotal FIREFLY-1 trial of tovorafenib (DAY101) in relapsed pediatric low-grade glioma
Jun 06, 2022: Verastem Oncology provides update on RAMP 201 study evaluating VS-6766 defactinib in low-grade serous ovarian cancer
May 23, 2022: Day One announces first patients dosed in phase 1b/2 combination study with tovorafenib (DAY101) and pimasertib in RAF-altered solid tumors
May 18, 2022: Verastem Oncology awarded Pancreatic Cancer Action Network’s first therapeutic Accelerator Award to evaluate the combination of VS-6766 and Defactinib in front-line metastatic pancreatic cancer
Apr 08, 2022: Jazz Pharmaceuticals presents pre-clinical data for pan-RAF inhibitor JZP815, including pharmacokinetic properties and efficacy in multiple solid tumor types
Mar 28, 2022: Verastem Oncology provides financial update to support development of VS-6766 and defactinib in RAS pathway-driven tumors
Mar 08, 2022: Jazz Pharmaceuticals to present Pan-RAF inhibitor pre-clinical data at American Association for Cancer Research (AACR) 2022 Annual Meeting
Nov 22, 2021: Day One announces first patient dosed in phase 2 monotherapy study in RAF-altered solid tumors
Nov 03, 2021: Day One announces presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting
Sep 19, 2021: ICR says drug combo demonstrates effectiveness in ovarian cancer trial
Sep 09, 2021: Bayer to present abstracts on Stivarga (regorafenib)at ESMO Congress 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Apollomics Inc
Bayer AG
Chengdu Fanxi Biopharma Co Ltd
Deciphera Pharmaceuticals Inc
Hanmi Pharmaceuticals Co Ltd
Jazz Pharmaceuticals Plc
Metagone Biotech Inc
Novartis AG
Quanta Therapeutics Inc
Samjin Pharm Co Ltd
Sirnaomics Ltd
SyntheX Inc
Takeda Pharmaceutical Co Ltd
Verastem Inc
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
(MG-005 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(MG-010 + sorafenib) - Drug Profile
Product Description
Mechanism Of Action
History of Events
APL-102 - Drug Profile
Product Description
Mechanism Of Action
History of Events
avutometinib - Drug Profile
Product Description
Mechanism Of Action
History of Events
belvarafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
DCBCI-0902 - Drug Profile
Product Description
Mechanism Of Action
DCC-3084 - Drug Profile
Product Description
Mechanism Of Action
FNX-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
FYA-1001 - Drug Profile
Product Description
Mechanism Of Action
JZP-815 - Drug Profile
Product Description
Mechanism Of Action
History of Events
naporafenibum - Drug Profile
Product Description
Mechanism Of Action
History of Events
regorafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
SJP-1601 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SJP-601 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit FLT, FLT3, FLT4, FMS, c-KIT, LYN, RAF1, RET, PDGFRa and PDGFRb for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit Pan-RAF Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit CRAF and BRAF for Oncology - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit RAF for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit RAF1 for Unspecified Cancer - Drug Profile
Product Description
Mechanism Of Action
STP-902 - Drug Profile
Product Description
Mechanism Of Action
STX-200 - Drug Profile
Product Description
Mechanism Of Action
tovorafenib - Drug Profile
Product Description
Mechanism Of Action
History of Events
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Dormant Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Discontinued Products
RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Nov 11, 2022: Day One announces upcoming presentations at 2022 Society for Neuro-Oncology Annual Meeting
Oct 04, 2022: Verastem Oncology announces RAMP VS-6766 clinical trials and corporate updates
Sep 21, 2022: Global Coalition for Adaptive Research announces that Regorafenib has completed follow-up in the Gbm Agile trial for patients with glioblastoma
Jun 15, 2022: FDA grants IND clearance for Jazz and Redx’s cancer drug application
Jun 12, 2022: Day One announces positive initial data from pivotal FIREFLY-1 trial of tovorafenib (DAY101) in relapsed pediatric low-grade glioma
Jun 06, 2022: Verastem Oncology provides update on RAMP 201 study evaluating VS-6766 defactinib in low-grade serous ovarian cancer
May 23, 2022: Day One announces first patients dosed in phase 1b/2 combination study with tovorafenib (DAY101) and pimasertib in RAF-altered solid tumors
May 18, 2022: Verastem Oncology awarded Pancreatic Cancer Action Network’s first therapeutic Accelerator Award to evaluate the combination of VS-6766 and Defactinib in front-line metastatic pancreatic cancer
Apr 08, 2022: Jazz Pharmaceuticals presents pre-clinical data for pan-RAF inhibitor JZP815, including pharmacokinetic properties and efficacy in multiple solid tumor types
Mar 28, 2022: Verastem Oncology provides financial update to support development of VS-6766 and defactinib in RAS pathway-driven tumors
Mar 08, 2022: Jazz Pharmaceuticals to present Pan-RAF inhibitor pre-clinical data at American Association for Cancer Research (AACR) 2022 Annual Meeting
Nov 22, 2021: Day One announces first patient dosed in phase 2 monotherapy study in RAF-altered solid tumors
Nov 03, 2021: Day One announces presentation at 2021 Connective Tissue Oncology Society (CTOS) Virtual Annual Meeting
Sep 19, 2021: ICR says drug combo demonstrates effectiveness in ovarian cancer trial
Sep 09, 2021: Bayer to present abstracts on Stivarga (regorafenib)at ESMO Congress 2021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Apollomics Inc, 2022
Pipeline by Bayer AG, 2022
Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2022
Pipeline by Deciphera Pharmaceuticals Inc, 2022
Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Pipeline by Jazz Pharmaceuticals Plc, 2022
Pipeline by Metagone Biotech Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by Quanta Therapeutics Inc, 2022
Pipeline by Samjin Pharm Co Ltd, 2022
Pipeline by Sirnaomics Ltd, 2022
Pipeline by SyntheX Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by Verastem Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Apollomics Inc, 2022
Pipeline by Bayer AG, 2022
Pipeline by Chengdu Fanxi Biopharma Co Ltd, 2022
Pipeline by Deciphera Pharmaceuticals Inc, 2022
Pipeline by Hanmi Pharmaceuticals Co Ltd, 2022
Pipeline by Jazz Pharmaceuticals Plc, 2022
Pipeline by Metagone Biotech Inc, 2022
Pipeline by Novartis AG, 2022
Pipeline by Quanta Therapeutics Inc, 2022
Pipeline by Samjin Pharm Co Ltd, 2022
Pipeline by Sirnaomics Ltd, 2022
Pipeline by SyntheX Inc, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by Verastem Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
